Nxera Pharma clinches millions from autoimmune disease deal
It has entered an assignment agreement with Viatris Inc, a global healthcare company, and Idorsia Pharmaceuticals Ltd to develop and commercialise cenerimod – a clinical-stage immunology candidate for autoimmune diseases.
The deal applies to Japan, South Korea and certain countries in the APAC region excluding China.
Nxera, based locally at Granta Park, will receive an upfront payment of $10 million from Viatris and is eligible to receive a milestone payment upon regulatory approval of cenerimod in Japan plus royalties on net sales should it be commercialised in the assigned territories. Nxera will pay no option exercise fee or make any other payments to Idorsia in relation to cenerimod.
The agreement was signed concurrently with Nxera’s assignment of its option to these same rights from Idorsia Pharmaceuticals under an agreement in July 2023 to acquire Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd.
Viatris will be the exclusive owner of cenerimod rights in Japan and APAC (ex-China). Viatris gained exclusive rights to cenerimod in all other territories from Idorsia through a research and development agreement signed in February 2024 and following this agreement with Nxera, now owns exclusive global rights to the candidate.
Cenerimod, a highly selective, oral sphingosine-1-phosphate receptor 1 (S1P1) modulator, was discovered by Idorsia and is being developed by Viatris and Idorsia for multiple immune disorders, including in Phase 3 trials as a potential first-in-class, oral therapy for systemic lupus erythematosus.
Dr. Makoto Sugita, EVP, CMO and President of Nxera Pharma Japan, said: “Cenerimod has demonstrated compelling disease-modifying activity across multiple autoimmune disorders and already has become a key development asset for Viatris within its immunology platform.
“In gaining and transferring Japan and APAC (ex-China) rights to Viatris, we are confident that cenerimod is in the best place to be advanced to fulfil its potential for patients while at the same time maximising value for Nxera shareholders.”